This is not the latest version of this item. The latest version can be found here.
Immunotherapy-induced antibodies to endogenous retroviral envelope glycoprotein confer tumor protection in mice
Name
journal.pone.0248903.pdf
Description
Published version
Size
1.96 MB
Format
Adobe PDF
Checksum (MD5)
c7b53911fbca7d136ec1b8990bc9ac5d
Author(s)
Kang, Byong H
Momin, Noor
Moynihan, Kelly D
Silva, Murillo
Li, Yingzhong
Irvine, Darrell J
Wittrup, K Dane
Date Issued
2021
Journal
PLoS ONE
Publisher
Public Library of Science (PLoS)
Version
Final published version
Abstract
Following curative immunotherapy of B16F10 tumors, ~60% of mice develop a strong antibody response against cell-surface tumor antigens. Their antisera confer prophylactic protection against intravenous challenge with B16F10 cells, and also cross-react with syngeneic and allogeneic tumor cell lines MC38, EL.4, 4T1, and CT26. We identified the envelope glycoprotein (env) of a murine endogenous retrovirus (ERV) as the antigen accounting for the majority of this humoral response. A systemically administered anti-env monoclonal antibody cloned from such a response protects against tumor challenge, and prophylactic vaccination against the env protein protects a majority of naive mice from tumor establishment following subcutaneous inoculation with B16F10 cells. These results suggest the potential for effective prophylactic vaccination against analogous HERV-K env expressed in numerous human cancers.
Terms of Use
Creative Commons Attribution 4.0 International license
Persistent DSpace Link
DOI of Published Version
10.1371/journal.pone.0248903
